Clinical use of the III generation calcium antagonist Amlotopin the treatment of patients with cardiovascular disease
Despite the facts, revealing the mechanisms of pathogenesis and enhancing the effectiveness of the treatment of cardiovascular disease (CVD), the latter continues to be the leading cause of death and disability in the population. In this regard, the search for new treatments for CVD remains the most...
Main Authors: | V. S Zadionchenko, G. G Shehyan, A. A Yalymov |
---|---|
Format: | Article |
Language: | English |
Published: |
Concilium Medicum
2013-12-01
|
Series: | КардиоСоматика |
Subjects: | |
Online Access: | https://cardiosomatics.orscience.ru/2221-7185/article/view/45033 |
Similar Items
-
Combination of dihydropyridine and non-dihydropyridine calcium antagonists in patients with arterial hypertension and coronary heart disease: efficacy and safety
by: B. G. Iskanderov, et al.
Published: (2005-12-01) -
Outcomes following calcium channel blocker exposures reported to a poison information center
by: Mikkel B. Christensen, et al.
Published: (2018-11-01) -
CALCIUM ANTAGONISTS IN CLINICAL PRACTICE: FOCUS ON METABOLIC AND VASCULAR EFFECTS
by: D. V. Nebieridze
Published: (2015-12-01) -
The role of calcium channel blockers in wound healing
by: Hoda Mojiri-Forushani
Published: (2018-12-01) -
Three calcium antagonists: a place of everyone in treatment arterial hypertension (ALTERNATIVE study)
by: Irina Evgen'evna Chazova, et al.
Published: (2009-12-01)